Advertisement

Topics

Opsona Therapeutics Ltd Company Profile

00:40 EST 23rd November 2017 | BioPortfolio

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin. Opsona's lead product, a fully human monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR-2) has demonstrated activity in a number of animal models and was recently tested in a phase 1 clinical trial in healthy volunteers. Following successful completion of the phase 1 trial, the company plans to conduct a two-part multi-centered, double blinded and placebo controlled clinical study to evaluate the safety, tolerability and efficacy of OPN 305 in renal transplant patients at high risk of Delayed Graft Function (DGF) as the first clinical target indication for the development of OPN-305 to be initiated in 2012. In May 2009 the company announced the completion of a € 21.3 million equity funding with an international investor consortium including: Inventages Venture Capital, Novartis Venture Fund, Roche Venture Fund, Seroba-Kernel Life Sciences, Fountain Healthcare Partners and Enterprise Ireland. Further information is available at http://www.opsona.com/.


News Articles [530 Associated News Articles listed on BioPortfolio]

Opsona Therapeutics Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24082017] Prices from USD $250

SummaryOpsona Therapeutics Ltd Opsona is a biopharmaceutical company that conducts research, develops and commercializes new treatment for the autoimmune and inflammatory diseases and cancers. The com...

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC.

Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.

ProQR spins out Amylon Therapeutics for CNS therapeutics

ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of inst...

Gouty Arthritis Gout Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1500

DelveInsight's, Gouty Arthritis Gout Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Gouty Arthritis Gout. The key objective of the report is to estab...

Capricor Therapeutics to Present at the Piper Jaffray Healthcare Conference

About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biolog...

Breakfast Technical Briefing on Biotech Stocks -- Cytori Therapeutics, Sorrento Therapeutics, ...

http://dailystocktracker.com/register/ Cytori Therapeutics San Diego, Californiaheadquartered Cytori Therapeutics Inc.'s shares dropped 2.15%, closing Monday's trading session at $0.39. The stock ...

RaNA Therapeutics Relaunches as Translate Bio to Advance RNA Therapeutics

Tuesday, June 27th 2017 at 11:00am UTC — Company Expands Executive Leadership Team with Key Appointments in Early 2017 — CAMBRIDGE, Mass.–(BUSINESS WIRE)– RaNA Therapeutics tod...

Clinical Trials [122 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1172 Associated Companies listed on BioPortfolio]

Opsona Therapeutics Ltd.

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of majo...

Opsona Therapeutics Ltd

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of majo...

Opsona Therapeutics Limited

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of majo...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Opsona Therapeutics Ltd" on BioPortfolio

We have published hundreds of Opsona Therapeutics Ltd news stories on BioPortfolio along with dozens of Opsona Therapeutics Ltd Clinical Trials and PubMed Articles about Opsona Therapeutics Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Opsona Therapeutics Ltd Companies in our database. You can also find out about relevant Opsona Therapeutics Ltd Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...


Corporate Database Quicklinks



Searches Linking to this Company Record